Patient-reported outcomes in ductal carcinoma in situ: A systematic review

European Journal of Cancer

Volumn 71, Issue , 2017, Pages 95-108

  King, Madeleine T ^a,b   Winters, Zoë E ^c   Olivotto, Ivo A ^d   Spillane, Andrew J ^b,e   Chua, Boon H ^f   Saunders, Christobel ^g   Westenberg, A Helen ^h   Mann, G Bruce ^f   Burnett, Petrina ⁱ   Butow, Phyllis ^a   Rutherford, Claudia ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d UNIVERSITY OF CALGARY   (Canada)

^e UNIVERSITY OF SYDNEY   (Australia)

^f UNIVERSITY OF MELBOURNE   (Australia)

^g UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^h NONE   (Netherlands)

ⁱ WA Cancer Physiotherapy Centre   (Australia)

Author keywords

Anxiety; Body image; Carcinoma, intraductal, noninfiltrating; Depression; Pain; Patient outcome assessment; Quality of life; Sexuality; Stress, psychological

Indexed keywords

ANXIETY DISORDER; BODY IMAGE; BREAST CANCER; BREAST PROSTHESIS; CANCER DIAGNOSIS; CANCER SURGERY; CANCER THERAPY; CINAHL; DEPRESSION; EMBASE; HUMAN; INTRADUCTAL CARCINOMA; MANAGED CARE; MASTECTOMY; MEDLINE; MORBIDITY; PATIENT-REPORTED OUTCOME; PRIORITY JOURNAL; PSYCINFO; QUALITY OF LIFE; QUANTITATIVE ANALYSIS; QUANTITATIVE STUDY; RECURRENT DISEASE; REVIEW; RISK FACTOR; SCOPUS; SEXUALITY; SYSTEMATIC REVIEW; ANXIETY; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FATIGUE; FEMALE; HEALTH STATUS; MENTAL STRESS; PSYCHOLOGY;

ANXIETY; BODY IMAGE; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FATIGUE; FEMALE; HEALTH STATUS; HUMANS; PATIENT REPORTED OUTCOME MEASURES; QUALITY OF LIFE; STRESS, PSYCHOLOGICAL;

EID: 85007170696     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2016.09.035     Document Type: Review

References (66)

1. [1] Fallowfield, L., Matthews, L., Francis, A., Jenkins, V., Rea, D., Low grade ductal carcinoma in situ (DCIS): how best to describe it?. Breast 23:5 (2014), 693–696, 10.1016/j.breast.2014.06.013.
2. [2] Ernster, V.L., Ballard-Barbash, R., Barlow, W.E., Zheng, Y., Weaver, D.L., Cutter, G., et al. Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst 94:20 (2002), 1546–1554.
3. [3] Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., Thun, M.J., Cancer statistics, 2007. CA Cancer J Clin 57:1 (2007), 43–66.
4. [4] Burstein, H.J., Polyak, K., Wong, J.S., Lester, S.C., Kaelin, C.M., Ductal carcinoma in situ of the breast. N Engl J Med 350:14 (2004), 1430–1441.
5. [5] National Health Service Breast Screening Programme (NHSBSP), NHS breast screening programme annual review 2008. 2008, NHSBSP, Sheffield http://www.cancerscreening.nhs.uk/breastscreen/publications/nhsbsp-annualreview2008.pdf.
6. [6] Cancer Australia, Report to the nation – breast cancer 2012., 2012, NSW.
7. [7] Esserman, L., Alvarado, M., Setting a research agenda for ductal carcinoma in situ that meets the current need for change. Ann Intern Med 160:7 (2014), 511–512, 10.7326/m14-0435.
8. [8] Narod, S.A., Iqbal, J., Giannakeas, V., Sopik, V., Sun, P., Breast cancer mortality after a diagnosis of ductal carcinoma in situ. JAMA Oncol 20:10 (2015), 888–896.
9. [9] Allegra, C.J., Aberle, D.R., Ganschow, P., Hahn, S.M., Lee, C.N., Millon-Underwood, S., et al. National Institutes of Health State-of-the-Science Conference statement: diagnosis and management of ductal carcinoma in situ September 22–24, 2009. J Natl Cancer Inst 102:3 (2010), 161–169.
10. [10] Boxer, M.M., Delaney, G.P., Chua, B.H., A review of the management of ductal carcinoma in situ following breast conserving surgery. Breast 22:6 (2013), 1019–1025, 10.1016/j.breast.2013.08.012.
11. [11] Early Breast Cancer Trialists’ Collaborative Group, Correa, C., McGale, P., Taylor, C., Wang, Y., Clarke, M., et al. Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr 2010:41 (2010), 162–177, 10.1093/jncimonographs/lgq039.
12. [12] Olivotto, I.A., Whelan, T.J., Parpia, S., Kim, D.H., Berrang, T., Truong, P.T., et al. Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy. J Clin Oncol 31:32 (2013), 4038–4045, 10.1200/JCO.2013.50.5511.
13. [13] Francis, A., Thomas, J., Fallowfield, L., Wallis, M., Bartlett, J.M.S., Brookes, C., et al. Addressing overtreatment of screen detected DCIS; the LORIS trial. Eur J Cancer 51:16 (2015), 2296–2303, 10.1016/j.ejca.2015.07.017.
14. [14] Forbes, J.F., Sestak, I., Howell, A., Bonanni, B., Bundred, N., Levy, C., et al. Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. Lancet, 2015, 10.1016/S0140-6736(15)01129-0.
15. [15] Independent UK Panel on Breast Cancer Screening, The benefits and harms of breast cancer screening: an independent review. Lancet 380:9855 (2012), 1778–1786, 10.1016/S0140-6736(12)61611-0.
16. [16] Cancer Australia. Overdiagnosis from mammographic screening https://canceraustralia.gov.au/publications-and-resources/position-statements/overdiagnosis-mammographic-screening2014.
17. [17] Smith, G.L., Toward minimizing overtreatment and under treatment of ductal carcinoma in situ in the United States. J Clin Oncol, 2016, 10.1200/jco.2015.66.2064.
18. [18] Elshof, L.E., Tryfonidis, K., Slaets, L., van Leeuwen-Stok, A.E., Skinner, V.P., Dif, N., et al. Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ—the LORD study. Eur J Cancer 51:12 (2015), 1497–1510, 10.1016/j.ejca.2015.05.008.
19. [19] Hwang, S., Comparison of operative versus medical endocrine therapy for low risk DCIS: the COMET trial. 2016, Patient-Centered Outcomes Research Institute, Illinois http://www.pcori.org/research-results/2016/comparison-operative-versus-medical-endocrine-therapy-low-risk-dcis-comet [Accessed 17th February 2016].
20. [20] Lemieux, J., Goodwin, P.J., Bordeleau, L.J., Lauzier, S., Théberge, V., Quality-of-life measurement in randomized clinical trials in breast cancer: an updated systematic review (2001–2009). J Natl Cancer Inst 103:3 (2011), 178–231, 10.1093/jnci/djq508.
21. [21] Berger, A.M., Lockhart, K., Agrawal, S., Variability of patterns of fatigue and quality of life over time based on different breast cancer adjuvant chemotherapy regimens. Oncol Nurs Forum 36:5 (2009), 563–570, 10.1188/09.onf.563-570.
22. [22] Bernhard, J., Zahrieh, D., Castiglione-Gertsch, M., Hurny, C., Gelber, R.D., Forbes, J.F., et al. Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients—the International Breast Cancer Study Group Trial VIII. J Clin Oncol 25:3 (2007), 263–270, 10.1200/jco.2005.04.5393.
23. [23] Groenvold, M., Fayers, P.M., Petersen, M.A., Mouridsen, H.T., Chemotherapy versus ovarian ablation as adjuvant therapy for breast cancer: impact on health-related quality of life in a randomized trial. Breast Cancer Res Treat 98:3 (2006), 275–284, 10.1007/s10549-006-9160-9.
24. [24] Brandberg, Y., Michelson, H., Nilsson, B., Bolund, C., Erikstein, B., Hietanen, P., et al. Quality of life in women with breast cancer during the first year after random assignment to adjuvant treatment with marrow-supported high-dose chemotherapy with cyclophosphamide, thiotepa, and carboplatin or tailored therapy with Fluorouracil, epirubicin, and cyclophosphamide: Scandinavian Breast Group Study 9401. J Clin Oncol 21:19 (2003), 3659–3664, 10.1200/jco.2003.07.020.
25. [25] Galalae, R.M., Michel, J., Siebmann, J.U., Kuchler, T., Eilf, K., Kimmig, B., Significant negative impact of adjuvant chemotherapy on health-related quality of life (HR-QoL) in women with breast cancer treated by conserving surgery and postoperative 3-D radiotherapy. Strahlenther Onkol 181:10 (2005), 645–651, 10.1007/s00066-005-1403-x.
26. [26] Land, S.R., Kopec, J.A., Yothers, G., Anderson, S., Day, R., Tang, G., et al. Health-related quality of life in axillary node-negative, estrogen receptor-negative breast cancer patients undergoing AC versus CMF chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel Project B-23. Breast Cancer Res Treat 86:2 (2004), 153–164, 10.1023/B: BREA.0000032983.87966.4e.
27. [27] Broeckel, J.A., Jacobsen, P.B., Balducci, L., Horton, J., Lyman, G.H., Quality of life after adjuvant chemotherapy for breast cancer. Breast Cancer Res Treat 62:2 (2000), 141–150.
28. [28] Hu, Y.Y., Weeks, C.M., In, H., Dodgion, C.M., Golshan, M., Chun, Y.S., et al. Impact of neoadjuvant chemotherapy on breast reconstruction. Cancer 117:13 (2011), 2833–2841, 10.1002/cncr.25872.
29. [29] Monrigal, E., Dauplat, J., Gimbergues, P., Le Bouedec, G., Peyronie, M., Achard, J.L., et al. Mastectomy with immediate breast reconstruction after neoadjuvant chemotherapy and radiation therapy. A new option for patients with operable invasive breast cancer. Results of a 20 years single institution study. Eur J Surg Oncol 37:10 (2011), 864–870, 10.1016/j.ejso.2011.07.009.
30. [30] Koch, L., Jansen, L., Brenner, H., Arndt, V., Fear of recurrence and disease progression in long-term (≥5 years) cancer survivors—a systematic review of quantitative studies. Psycho-Oncology 22:1 (2013), 1–11, 10.1002/pon.3022.
31. [31] Taylor, T.R., Huntley, E.D., Sween, J., Makambi, K., Mellman, T.A., Williams, C.D., et al. An exploratory analysis of fear of recurrence among African-American breast cancer survivors. Int J Behav Med 19:3 (2012), 280–287, 10.1007/s12529-011-9183-4.
32. [32] Koch, L., Bertram, H., Eberle, A., Holleczek, B., Schmid-Höpfner, S., Waldmann, A., et al. Fear of recurrence in long-term breast cancer survivors—still an issue. Results on prevalence, determinants, and the association with quality of life and depression from the Cancer Survivorship—a multi-regional population-based study. Psycho-Oncology 23:5 (2014), 547–554, 10.1002/pon.3452.
33. [33] Benson, J.R., Wishart, G.C., Predictors of recurrence for ductal carcinoma in situ after breast-conserving surgery. Lancet Oncol 14:9 (2013), 348–357.
34. [34] Dunne, C., Burke, J.P., Morrow, M., Kell, M.R., Effect of margin status on local recurrence after breast conservation and radiation therapy for ductal carcinoma in situ. J Clin Oncol 27:10 (2009), 1615–1620, 10.1200/jco.2008.17.5182.
35. [35] Nilsson, C., Valachis, A., The role of boost and hypofractionation as adjuvant radiotherapy in patients with DCIS: a meta-analysis of observational studies. Radiother Oncol 114:1 (2015), 50–55, 10.1016/j.radonc.2015.01.001.
36. [36] Calvert, M., Brundage, M., Jacobsen, P.B., Schunemann, H.J., Efficace, F., The CONSORT patient-reported outcome (PRO) extension: implications for clinical trials and practice. Health Qual Life Outcomes 11:184 (2013), 1477–7525.
37. [37] Efficace, F., Bottomley, A., Osoba, D., Gotay, C., Flechtner, H., D'Haese, S., et al. Beyond the development of health-related quality-of-life (HRQOL) measures: a checklist for evaluating HRQOL outcomes in cancer clinical trials—does HRQOL evaluation in prostate cancer research inform clinical decision making?. J Clin Oncol 21:18 (2003), 3502–3511.
38. [38] Kmet, L., Lee, R., Cook, L., Standard quality assessment criteria for evaluating primary research papers from a variety of fields. Health Technol Assess, 2004, 13.
39. [39] Centre for Reviews and Dissemination, Undertaking systematic reviews of research on effectiveness., 2001, University of York, York, UK http://www.york.ac.uk/inst/crd/report4.htm Report 4.
40. [40] Kennedy, F., Harcourt, D., Rumsey, N., The challenge of being diagnosed and treated for ductal carcinoma in situ (DCIS). Eur J Oncol Nurs 12:2 (2008), 103–111, 10.1016/j.ejon.2007.09.007.
41. [41] Kennedy, F., Harcourt, D., Rumsey, N., The shifting nature of women's experiences and perceptions of ductal carcinoma in situ. J Adv Nurs 68:4 (2012), 856–867, 10.1111/j.1365-2648.2011.05788.x.
42. [42] Brown, M., Koch, T., Webb, C., Information needs of women with non-invasive breast cancer. J Clin Nurs 9:5 (2000), 713–722, 10.1046/j.1365-2702.2000.00419.x.
43. [43] Wong, S.T., Chen, W., Bottorff, J.L., Hislop, T.G., Treatment decision making among Chinese women with DCIS. J Psychosoc Oncol 26:4 (2008), 53–73.
44. [44] Amichetti, M., Caffo, O., Arcicasa, M., Roncadin, M., Lora, O., Rigon, A., et al. Quality of life in patients with ductal carcinoma in situ of the breast treated with conservative surgery and postoperative irradiation. Breast Cancer Res Treat 54:2 (1999), 109–115, 10.1023/a:1006125602353.
45. [45] Bloom, J.R., Stewart, S.L., Napoles, A.M., Hwang, E.S., Livaudais, J.C., Karliner, L., et al. Quality of life of Latina and Euro-American women with ductal carcinoma in situ. Psycho-Oncology 22:5 (2013), 1008–1016, 10.1002/pon.3098.
46. [46] Bluman, L.G., Borstelmann, N.A., Rimer, B.K., Iglehart, J.D., Winer, E.P., Knowledge, satisfaction, and perceived cancer risk among women diagnosed with ductal carcinoma in situ. J Womens Health Gend Based Med 10:6 (2001), 589–598, 10.1089/15246090152543175.
47. [47] Rakovitch, E., Franssen, E., Kim, J., Ackerman, I., Pignol, J.P., Paszat, L., et al. A comparison of risk perception and psychological morbidity in women with ductal carcinoma in situ and early invasive breast cancer. Breast Cancer Res Treat 77:3 (2003), 285–293, 10.1023/a:1021853302033.
48. [48] Sackey, H., Sandelin, K., Frisell, J., Wickman, M., Brandberg, Y., Ductal carcinoma in situ of the breast. Long-term follow-up of health-related quality of life, emotional reactions and body image. Eur J Surg Oncol 36:8 (2010), 756–762, 10.1016/j.ejso.2010.06.016.
49. [49] van Gestel, Y.R.B.M., Voogd, A.C., Vingerhoets, A.J.J.M., Mols, F., Nieuwenhuijzen, G.A.P., van Driel, O.J.R., et al. A comparison of quality of life, disease impact and risk perception in women with invasive breast cancer and ductal carcinoma in situ. Eur J Cancer 43:3 (2007), 549–556, 10.1016/j.ejca.2006.10.010.
50. [50] Fosh, B., Hainsworth, A., Beumer, J., Howes, B., McLeay, W., Eaton, M., Cosmesis outcomes for sector resection for ductal carcinoma in situ (DCIS). Ann Surg Oncol 21:4 (2014), 1271–1275, 10.1245/s10434-013-3441-4.
51. [51] Ciervide, R., Dhage, S., Guth, A., Shapiro, R.L., Axelrod, D.M., Roses, D.F., et al. Five year outcome of 145 patients with ductal carcinoma in situ (DCIS) after accelerated breast radiotherapy. Int J Radiat Oncol Biol Phys, 83(2), 2012, 025.
52. [52] Kennedy, F., Harcourt, D., Rumsey, N., White, P., The psychosocial impact of ductal carcinoma in situ (DCIS): a longitudinal prospective study. Breast 19:5 (2010), 382–387.
53. [53] Lauzier, S., Maunsell, E., Levesque, P., Mondor, M., Robert, J., André, R., et al. Psychological distress and physical health in the year after diagnosis of DCIS or invasive breast cancer. Breast Cancer Res Treat 120:3 (2010), 685–691, 10.1007/s10549-009-0477-z.
54. [54] Liu, Y., Pérez, M., Aft, R.L., Massman, K., Robinson, E., Myles, S., et al. Accuracy of perceived risk of recurrence among patients with early-stage breast cancer. Cancer Epidemiol Biomarkers Prev 19:3 (2010), 675–680, 10.1158/1055-9965.epi-09-1051.
55. [55] Liu, Y., Pérez, M., Schootman, M., Aft, R.L., Gillanders, W.E., Ellis, M.J., et al. A longitudinal study of factors associated with perceived risk of recurrence in women with ductal carcinoma in situ and early-stage invasive breast cancer. Breast Cancer Res Treat 124:3 (2010), 835–844, 10.1007/s10549-010-0912-1.
56. [56] Liu, Y., Pérez, M., Schootman, M., Aft, R.L., Gillanders, W.E., Jeffe, D.B., Correlates of fear of cancer recurrence in women with ductal carcinoma in situ and early invasive breast cancer. Breast Cancer Res Treat 130:1 (2011), 165–173, 10.1007/s10549-011-1551-x.
57. [57] Nekhlyudov, L., Kroenke, C.H., Jung, I., Holmes, M.D., Colditz, G.A., Prospective changes in quality of life after ductal carcinoma-in-situ: results from the nurses’ health study. J Clin Oncol 24:18 (2006), 2822–2827, 10.1200/jco.2005.04.6219.
58. [58] Partridge, A., Adloff, K., Blood, E., Dees, E.C., Kaelin, C., Golshan, M., et al. Risk perceptions and psychosocial outcomes of women with ductal carcinoma in situ: longitudinal results from a cohort study. J Natl Cancer Inst 100:4 (2008), 243–251, 10.1093/jnci/djn010.
59. [59] Perez, M., Liu, Y., Schootman, M., Aft, R.L., Schechtman, K.B., Gillanders, W.E., et al. Changes in sexual problems over time in women with and without early-stage breast cancer. Menopause 17:5 (2010), 924–937.
60. [60] Ruddy, K.J., Meyer, M.E., Giobbie-Hurder, A., Emmons, K.M., Weeks, J.C., Winer, E.P., et al. Long-term risk perceptions of women with ductal carcinoma in situ. Oncologist 18:4 (2013), 362–368, 10.1634/theoncologist.2012-0376.
61. [61] Bober, S.L., Giobbie-Hurder, A., Emmons, K.M., Winer, E., Partridge, A., Psychosexual functioning and body image following a diagnosis of ductal carcinoma in situ. J Sex Med 10:2 (2013), 370–377.
62. [62] Jeffe, D.B., Perez, M., Liu, Y., Collins, K.K., Aft, R.L., Schootman, M., Quality of life over time in women diagnosed with ductal carcinoma in situ, early-stage invasive breast cancer, and age-matched controls. Breast Cancer Res Treat 134:1 (2012), 379–391, 10.1007/s10549-012-2048-y.
63. [63] National Breast Cancer Centre, Psychosocial clinical practice guidelines: information, support and counselling for women with breast cancer Woolloomooloo. Natl Breast Cancer Cent, 2000 CP61.
64. [64] Jassim, G.A., Whitford, D.L., Hickey, A., Carter, B., Psychological interventions for women with non-metastatic breast cancer. Cochrane Database Syst Rev, 5, 2015, CD008729, 10.1002/14651858.CD008729.pub2.
65. [65] Faller, H., Schuler, M., Richard, M., Heckl, U., Weis, J., Küffner, R., Effects of psycho-oncologic interventions on emotional distress and quality of life in adult patients with cancer: systematic review and meta-analysis. J Clin Oncol, 2013, 10.1200/jco.2011.40.8922.
66. [66] Chua, B., Radiation doses and fractionation schedules in non-low risk ductal carcinoma in situ (DCIS) of the breast (DCIS):. 2016 NCT00470236 ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/study/NCT00470236? [Accessed 18th February 2016].